{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-22-071230","form_type":"8-K","ticker":"ORMP","cik":"0001176309","company_name":"ORAMED PHARMACEUTICALS INC.","filed_at":"2022-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.830373+00:00","generated_at":"2026-06-21T22:19:37.930894+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Oramed Q3 2022: loss per share $0.18; cash $160M; positive NASH and COVID-19 vaccine data","bullets":["Cash and investments approximately $160M as of September 30, 2022.","R&D expenses decreased 12% YoY to $5.3M; basic loss per share improved to $0.18 from $0.21.","Sales & marketing expense up 169% to $463K; G&A up 60% to $3.1M due to stock-based compensation.","Reported positive Phase 2 NASH data and positive initial Phase 1 oral COVID-19 vaccine results.","Phase 3 oral insulin (ORMD-0801) topline data expected in January 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-22-071230","json":"https://secwatch.observer/filing/0001213900-22-071230.json","markdown":"https://secwatch.observer/filing/0001213900-22-071230.md","text":"https://secwatch.observer/filing/0001213900-22-071230.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1176309/000121390022071230/0001213900-22-071230-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1176309/000121390022071230/ea168314-8k_oramed.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T22:19:37.930894+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a14ec4fa30a1964dd0a1044295fdb9a1b3dabe43","claim":"ORAMED PHARMACEUTICALS INC. reported the quarter ended September 30, 2022 results: EPS $0.18.","evidence_excerpt":"Basic and diluted loss per share of common stock for the three month period ended September 30, 2022 decreased by 14% to $0.18, compared to $0.21 for the three month period ended September 30, 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390022071230/0001213900-22-071230-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2022"},{"label":"EPS","value":"$0.18"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}